Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma. / Efectividad y seguridad en vida real de nivolumab en pacientes con linfoma de hodgkin clásico en recaída o refractario.

OBJECTIVE: The primary objective is to describe the real-life effectiveness and safety of nivolumab treatment in patients with relapsed or refractory classical Hodgkin's lymphoma. The secondary objective is to describe the therapeutic management after nivolumab monotherapy. METHOD: Observational, retrospective, multidisciplinary study including all patients with relapsed or refractory classical Hodgkin's lymphoma treated with nivolumab monotherapy from November 2015 to March 2023. Patient and treatment-related variables were collected. Effectiveness was measured as overall response rate, progression-free survival and overall survival. Safety was measured as percentage of patients with adverse effects and severity. RESULTS: Thirteen patients were included, median age 37.5 years (RIQ: 25.3-54.7), 84.6% male. The median number of previous lines of therapy was 3 (RIQ: 2.0-4.5), including autologous hematopoietic stem cell transplantation (84.6%) and brentuximab vedotin (100%). All received nivolumab 3 mg/kg/14 days, with a median of 11 cycles (RIQ: 6.5-20.5) per patient. Median time on treatment was 4.9 months (RIQ: 3.0-9.6) and median follow-up time was 9.2 months (RIQ: 5.6-32.3). Complete response was achieved by 3 patients (23.1%), partial response by 3 (23.1%), stable disease by 3 (23.1%) and progression by 4 (30.8%). The objective response rate was 46.2%. Median progression-free survival was 23.9 months (95%CI: 0-49.1), median overall survival was not reached. At the study cutoff date, five patients had died (38.5%), four were in complete remission without active treatment (30.8%) and four were continuing treatment (30.8%). Adverse events occurred in 76.9% of patients, 44% of severity ≥3, the most frequent being hypothyroidism and hepatotoxicity. One patient discontinued treatment due to pneumonitis, two suffered treatment delays (thrombocytopenia and hypertransaminemia) and one changed the regimen to monthly (pulmonary toxicity). CONCLUSIONS: Nivolumab in the treatment of relapsed or refractory classical Hodgkin's lymphoma has confirmed in the study sample favorable effectiveness data, expressed as objective response rate of 46.2% and clinical benefit of 69.2%. Safety was acceptable, manageable, and consistent with that described in the literature.

Development and validation of a prognostic nomogram for the renal relapse of lupus nephritis / Desarrollo y validación de un nomograma pronóstico para la recaída renal de la nefritis lúpica

Objectives This study aims to assess the risk of relapse after complete remission (CR) and partial remission (PR), and to develop a prognostic nomogram predicting the probability in lupus nephritis (LN) patients. Methods Data from patients with LN who had been in remission were collected as a training cohort. The prognostic factors were analyzed using the univariable and multivariable Cox model for the training group. A nomogram was then developed using significant predictors in multivariable analysis. Both discrimination and calibration were assessed by bootstrapping with 100 resamples. Results A total of 247 participants were enrolled, including 108 in the relapse group and 139 in the no relapse group. In multivariate Cox analysis, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), erythrocyte sedimentation rate (ESR), complement 1q (C1q), and antiphospholipid (aPL), anti-Sm antibody were found to be significant for predicting relapse rates. The prognostic nomogram including the aforementioned factors effectively predicted 1- and 3-year probability of flare-free. Moreover, a favorable consistency between the predicted and actual survival probabilities was demonstrated using calibration curves. Conclusions High SLEDAI, ESR, and positive aPL, anti-Sm antibody are potential risk factors for LN flare, while high C1q can reduce its recurrence. The visualized model we established can help predict the relapse risk of LN and aid clinical decision-making for individual patients (AU)

Objetivos Este estudio pretende evaluar el riesgo de recaída tras la remisión completa y la remisión parcial, y desarrollar un nomograma pronóstico que prediga la probabilidad en pacientes con nefritis lúpica (NL). Métodos Se recogieron datos de pacientes con NL que habían estado en remisión como cohorte de entrenamiento. Se analizaron los factores pronósticos utilizando el modelo COX univariable y multivariable para el grupo de entrenamiento. A continuación se desarrolló un nomograma utilizando los predictores significativos en el análisis multivariable. Tanto la discriminación como la calibración se evaluaron mediante bootstrapping con 100 remuestreos. Resultados Se inscribió a un total de 247 participantes, incluidos 108 en el grupo de recaída y 139 en el grupo sin recaída. En el análisis multivariante de Cox, el índice de actividad de la enfermedad lúpica eritematosa sistémica (SLEDAI), la velocidad de sedimentación globular (VSG), el complemento 1q (C1q) y los anticuerpos antifosfolípidos (aPL) y anti-Sm resultaron significativos para predecir las tasas de recaída. El nomograma pronóstico que incluía los factores mencionados predijo eficazmente la probabilidad a 1 y a 3 años de estar libre de reagudizaciones. Además, se demostró una coherencia favorable entre las probabilidades de supervivencia previstas y las reales mediante curvas de calibración. Conclusiones SLEDAI alto, VSG y aPL positivo, anticuerpos anti-Sm son factores de riesgo potenciales de reagudización de la NL, mientras que C1q alto puede reducir su recurrencia. El modelo visualizado que establecimos puede ayudar a predecir el riesgo de recidiva de la NL y ayudar a la toma de decisiones clínicas para pacientes individuales (AU)

Validación ecológica del programa FORT (Fear of Cancer Recurrence Therapy): una adaptación del español mexicano al español castellano: reporte preliminar / Ecological validation of Fear of Cancer Recurrence Therapy from Mexican to european Spanish for breast cancer patients: Preliminary repor

Introducción: El miedo a la recaída es uno de los problemas psicológicos en los pacientes con cáncer, más específicos. El aumento en la esperanza de vida en el paciente oncológico, y la supervivencia, hace que cada vez más conozcamos las consecuencias emocionales, y vivir con el llamado Síndrome de la Espada de Damocles es sin duda una de las más importantes. Este miedo a la recaída puede llegar a ser invalidante y por ello cada vez más se elaboran programas terapéuticos para poderlo combatir. Uno de los más conocidos es el FORT (Fear of Recurrence Therapy) elaborado por Maheu y Lebel y que en este momento está siendo adaptado a otros lenguajes y culturas. Una de ellas es la adaptación de Gálvez en México. Objetivo: Nuestro objetivo en el presente trabajo preliminar es presentar los primeros datos de adaptación de esta terapia del español mexicano al europeo. Método: El procedimiento seguido es la validación ecológica propuesta por Bernal en base al consenso de dos psicooncólogas expertas. Resultados: Después de valorar el cambio de diferentes conceptos y terminologías, se han valorado de forma independiente por parte de ambas psicooncólogas, las 8 dimensiones de Bernal con un alto índice Kappa (de 0,8 a 1). Conclusiones: Este es un estudio preliminar al que le va a seguir los mismos pasos para el manual de la paciente por parte de profesionales y de pacientes con cáncer de mama (AU)

Introduction: Fear of recurrence is one of the most specific psychological problems faced by cancer patients. Their increase in life expectancy, and survival, makes them increasingly aware of the emotional consequences, and living with the so-called Sword of Damocles Syndrome is undoubtedly one of the most important. Fear of recurrence can become disabling and affect their emotional well-being, leading to the development of therapeutic programs like FORT (Fear of Recurrence Therapy) developed by Maheu and Lebel. This therapy is being adapted to different languages and cultures, including Mexican Spanish by Gálvez. Objective: In this preliminary work, we aim to present the first data on adapting FORT from Mexican Spanish to European Spanish. Methods: The procedure used was to follow the ecological validation method proposed by Bernal, by two skilled psychooncologists. Results: The assessment of different concepts and terminologies by the two psychooncologists in an independent way, the analysis yielded a high Kappa index (from 0.8 to 1) for the 8 dimensions of Bernal. Conclusions: This preliminary study will be followed by a similar process for the patient manual by professionals and breast cancer patients (AU)

Seguimiento de los pacientes con pie Bot durante la pandemia del SARS CoV-2: frecuencia y causas del abandono del tratamiento

Introducción: El pie Bot es la deformidad del pie más frecuente en pediatría. El pie se caracteriza por tener el tobillo equino, varo el retropié, aducto el antepié, y cavo el medio pie. Objetivos: describir la frecuencia y los motivos de abandono del tratamiento del pie Bot en una población pediátrica hospitalaria durante la pandemia (2020-2021). Materiales y Métodos: Estudio observacional descriptivo ambispectivo. Fueron incluidos por muestreo de casos consecutivos, niños de 0 a 6 años que se encontraban en seguimiento de pie Bot en el servicio de traumatología pediátrica y abandonaron el tratamiento. Los datos fueron recogidos de las historias clínicas y por entrevista telefónica con los padres. Variables demográficas, características de la deformidad, edad y escolaridad de la madre, antecedentes familiares de pie Bot y otras malformaciones, la recurrencia, causas del abandono de tratamiento. Los datos fueron analizados en SPSS v21.Se solicitó el consentimiento informado de los padres. Resultados : El 25% (101/404) de los pacientes en seguimiento en el hospital, en el periodo de 2020-2021 abandonaron el tratamiento. Ingresaron al estudio 62 pacientes. El 95% presentaron recurrencia y recibieron tratamiento quirúrgico. La causa más frecuente de abandono del tratamiento de acuerdo con los padres fueron las dificultades derivadas de la pandemia. Conclusiones: La frecuencia de abandono de tratamiento fue del 25,2%, con predominio del sexo masculino. El 95% presentaron recaída y recibieron tratamiento quirúrgico (Tenotomía de Aquiles). La causa más frecuente de abandono de tratamiento fue la pandemia.

Introduction: Clubfoot is the most frequent foot deformity in pediatrics. The foot is characterized by having an equine ankle, a varus hindfoot, an adducted forefoot, and a dig in the midfoot. Objectives: to describe the frequency and reasons for abandoning Clubfoot treatment in a pediatric hospital population in the pandemic (2020-2021). Materials and Methods: This was an ambispective, descriptive and observational study. Consecutive case sampling included children from 0 to 6 years of age who were undergoing Clubfoot follow-up in the pediatric trauma service and abandoned treatment. Data were collected from medical records and by telephone interview with parents. The variables were: demographics, characteristics of the deformity, age and education of the mother, family history of Clubfoot and other malformations, recurrence and causes of treatment abandonment. Data were analyzed in SPSS v21. Parental informed consent was requested. Results: During the 2020-2021 period, 25% (101/404) of the patients being monitored at the hospital abandoned treatment. 62 patients were enrolled in the study. 95% presented recurrence and received surgical treatment. The most frequent cause of treatment abandonment, according to the parents, was the difficulties caused by the pandemic. Conclusions: The frequency of treatment abandonment was 25.2%, with a predominance of males. 95% presented relapse and received surgical treatment (Achilles Tenotomy). The most frequent cause of treatment abandonment was the pandemic.

Development and validation of a prognostic nomogram for the renal relapse of lupus nephritis.

OBJECTIVES: This study aims to assess the risk of relapse after complete remission (CR) and partial remission (PR), and to develop a prognostic nomogram predicting the probability in lupus nephritis (LN) patients. METHODS: Data from patients with LN who had been in remission were collected as a training cohort. The prognostic factors were analyzed using the univariable and multivariable Cox model for the training group. A nomogram was then developed using significant predictors in multivariable analysis. Both discrimination and calibration were assessed by bootstrapping with 100 resamples. RESULTS: A total of 247 participants were enrolled, including 108 in the relapse group and 139 in the no relapse group. In multivariate Cox analysis, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), erythrocyte sedimentation rate (ESR), complement 1q (C1q), and antiphospholipid (aPL), anti-Sm antibody were found to be significant for predicting relapse rates. The prognostic nomogram including the aforementioned factors effectively predicted 1- and 3-year probability of flare-free. Moreover, a favorable consistency between the predicted and actual survival probabilities was demonstrated using calibration curves. CONCLUSIONS: High SLEDAI, ESR, and positive aPL, anti-Sm antibody are potential risk factors for LN flare, while high C1q can reduce its recurrence. The visualized model we established can help predict the relapse risk of LN and aid clinical decision-making for individual patients.

Myosin 1g as a high-risk biomarker in a pediatric patient with lineage switch from acute lymphoblastic leukemia to myeloid phenotype.

BACKGROUND: Myosin 1g (Myo1g) has recently been identified as a potential diagnostic biomarker in childhood acute lymphocytic leukemia (ALL). CASE REPORT: We describe the case of a 1-year-old Mexican female patient. Although initially studied for hepatomegaly, an infectious or genetic etiology was excluded. Liver biopsy showed infiltration by neoplastic B-cell precursors (BCPs), and bone marrow (BM) aspirate showed 14.5% of BCPs. In a joint session of the oncology, hematology, and pathology departments, low-risk (LR) BCP-ALL of hepatic origin with aberrant myeloid markers was diagnosed. Although treatment was initiated, the patient presented early with BM relapse. Modest overexpression of Myo1g was observed from the onset. However, at the end of the steroid window, expression increased significantly and remained elevated during this first relapse to BM. The parents refused hematopoietic stem cell transplantation, but she continued chemotherapy. After a second BM relapse at 5 years of age, the phenotype switched to myeloid. Her parents then opted for palliative care, and the patient died two months later at home. CONCLUSIONS: This case shows the potential use of Myo1g in clinical practice as a high-risk indicator. Myo1g monitoring may reveal a high risk and relapse trend, even when typical parameter values are not altered: Myo1g could be used to classify patients from low to high risk from diagnosis, allowing patients to promptly receive the best treatment and potentially modifying prognosis and survival.

INTRODUCCIÓN: Recientemente se ha identificado a miosina 1g (Myo1g) como un potencial biomarcador de diagnóstico en la leucemia linfoblástica aguda (LLA) infantil. CASO CLÍNICO: Se describe el caso de una paciente mexicana de 1 año de edad. Aunque inicialmente se estudió por hepatomegalia, se descartó una etiología infecciosa o genética. La biopsia hepática mostró infiltración por precursores de células B neoplásicas (PCB) y un aspirado de médula ósea (MO) mostró 14.5% de PCB. En una sesión conjunta de los departamentos de oncología, hematología y patología, se diagnosticó PCB-LLA de bajo riesgo de origen hepático con marcadores mieloides aberrantes. Aunque se inició tratamiento, la paciente presentó tempranamente recaída de MO. Se observó una modesta sobreexpresión de Myo1g. Sin embargo, al final de la ventana de esteroides, la expresión aumentó considerablemente y permaneció elevada durante esta primera recaída a MO. El trasplante de células madre hematopoyéticas fue rechazado por los padres, pero se continuó con la quimioterapia. Tras una segunda recaída de MO a los 5 años, el fenotipo cambió a mieloide. Sus padres optaron entonces por cuidados paliativos y la paciente falleció dos meses después en su domicilio. CONCLUSIONES: Este caso muestra el potencial uso de Myo1g como indicador de alto riesgo en la práctica clínica. El seguimiento de Myo1g puede revelar una tendencia de alto riesgo y recaídas, incluso cuando los valores de los parámetros rutinarios son aparentemente normales; Myo1g podría utilizarse para clasificar a los pacientes de bajo a alto riesgo desde el diagnóstico, lo que permitiría que los pacientes reciban el mejor tratamiento de manera oportuna, modificando potencialmente el pronóstico y la supervivencia.

Myosin 1g as a high-risk biomarker in a pediatric patient with lineage switch from acute lymphoblastic leukemia to myeloid phenotype / Miosina 1g como un marcador de alto riesgo en una paciente pediátrica con cambio de linaje de leucemia linfoblástica aguda a fenotipo mieloide

Abstract Background: Myosin 1g (Myo1g) has recently been identified as a potential diagnostic biomarker in childhood acute lymphocytic leukemia (ALL). Case report: We describe the case of a 1-year-old Mexican female patient. Although initially studied for hepatomegaly, an infectious or genetic etiology was excluded. Liver biopsy showed infiltration by neoplastic B-cell precursors (BCPs), and bone marrow (BM) aspirate showed 14.5% of BCPs. In a joint session of the oncology, hematology, and pathology departments, low-risk (LR) BCP-ALL of hepatic origin with aberrant myeloid markers was diagnosed. Although treatment was initiated, the patient presented early with BM relapse. Modest overexpression of Myo1g was observed from the onset. However, at the end of the steroid window, expression increased significantly and remained elevated during this first relapse to BM. The parents refused hematopoietic stem cell transplantation, but she continued chemotherapy. After a second BM relapse at 5 years of age, the phenotype switched to myeloid. Her parents then opted for palliative care, and the patient died two months later at home. Conclusions: This case shows the potential use of Myo1g in clinical practice as a high-risk indicator. Myo1g monitoring may reveal a high risk and relapse trend, even when typical parameter values are not altered: Myo1g could be used to classify patients from low to high risk from diagnosis, allowing patients to promptly receive the best treatment and potentially modifying prognosis and survival.

Resumen Introducción: Recientemente se ha identificado a miosina 1g (Myo1g) como un potencial biomarcador de diagnóstico en la leucemia linfoblástica aguda (LLA) infantil. Caso clínico: Se describe el caso de una paciente mexicana de 1 año de edad. Aunque inicialmente se estudió por hepatomegalia, se descartó una etiología infecciosa o genética. La biopsia hepática mostró infiltración por precursores de células B neoplásicas (PCB) y un aspirado de médula ósea (MO) mostró 14.5% de PCB. En una sesión conjunta de los departamentos de oncología, hematología y patología, se diagnosticó PCB-LLA de bajo riesgo de origen hepático con marcadores mieloides aberrantes. Aunque se inició tratamiento, la paciente presentó tempranamente recaída de MO. Se observó una modesta sobreexpresión de Myo1g. Sin embargo, al final de la ventana de esteroides, la expresión aumentó considerablemente y permaneció elevada durante esta primera recaída a MO. El trasplante de células madre hematopoyéticas fue rechazado por los padres, pero se continuó con la quimioterapia. Tras una segunda recaída de MO a los 5 años, el fenotipo cambió a mieloide. Sus padres optaron entonces por cuidados paliativos y la paciente falleció dos meses después en su domicilio. Conclusiones: Este caso muestra el potencial uso de Myo1g como indicador de alto riesgo en la práctica clínica. El seguimiento de Myo1g puede revelar una tendencia de alto riesgo y recaídas, incluso cuando los valores de los parámetros rutinarios son aparentemente normales; Myo1g podría utilizarse para clasificar a los pacientes de bajo a alto riesgo desde el diagnóstico, lo que permitiría que los pacientes reciban el mejor tratamiento de manera oportuna, modificando potencialmente el pronóstico y la supervivencia.

Rendimiento de la PET/TC con 11C-colina en el seguimiento del cáncer de próstata / Effectiveness of 11C-choline PET/CT in prostate cancer surveillance

Objetivo Analizar el rendimiento diagnóstico de la PET/TC con 11C-colina en el seguimiento del cáncer de próstata (CaP), especialmente en pacientes con antígeno prostático específico (PSA)>1ng/ml. Material y métodos Se evaluaron retrospectivamente 329 exploraciones PET/TC con 11C-colina de 191 pacientes (68,2±7,2 años) con CaP con recaída bioquímica o en seguimiento (PSA en el momento de la PET/TC: 13,0±84,2ng/ml). El tratamiento inicial fue prostatectomía radical en 81 pacientes y otros tratamientos (radioterapia, quimioterapia, hormonoterapia) en 110. La PET/TC se adquirió 20min después de la inyección de 555-740MBq de 11C-colina. El seguimiento mínimo fue superior a 12 meses. Resultados Doscientas diecinueve (66,6%) de las 329 exploraciones PET/TC fueron positivas. El porcentaje de positivos fue significativamente mayor en los pacientes con otro tratamiento inicial diferente a la prostatectomía radical (85,6 frente a 43,6%, respectivamente). Ciento treinta PET/TC (59,4%) mostraron recidiva local, 48 (21,9%) a distancia y 41 (18,7%) local más a distancia. El abordaje terapéutico inicial se modificó en 139 casos (63,5%). De las 81 PET/TC con 11C-colina realizadas con PSA<1ng/ml, 23 (28,4%) fueron positivas. El abordaje terapéutico inicial se modificó en 9 (11,1%). Tres de 63 pacientes (4,8%) fallecieron por CaP. Conclusiones La PET/TC con 11C-colina demostró su eficacia en el seguimiento y la reestadificación del CaP, incluso en pacientes con PSA sérico<1ng/ml. El rendimiento diagnóstico fue diferente según el tratamiento inicial al que fueron sometidos los pacientes, siendo mayor en aquellos tratados inicialmente con otros tratamientos distintos de la PR prostatectomía radical (AU)

Aim Our aim was to analyse the performance of 11C-choline PET/CT in prostate cancer (PCa) surveillance, especially in patients with prostate specific antigen (PSA)<1ng/ml. Material and methods Three hundred and twenty-nine 11C-choline PET/CT examinations from 191 patients (68.2±7.2 years) submitted for PCa surveillance or biochemical recurrence were retrospectively evaluated (PSA at study was 13.0±84.2ng/ml). Main initial treatment was radical prostatectomy in 81 patients, and other treatments (radiotherapy, chemotherapy, hormonotherapy) in 110. PET/CT was acquired 20min after injection of 555-740MBq of 11C-choline. Minimum follow-up was 12 months. Results Two hundred and nineteen (66.6%) out of the 329 PET/CT examinations were positive. The percentage of positive examinations was significantly higher in patients with other initial treatment than radical prostatectomy compared to patients with radical prostatectomy (85.6 vs. 43.6%, respectively). One hundred and thirty PET/CT (59.4%) showed local recurrence, 48 (21.9%) distant recurrence, and 41 (18.7%) local plus distant recurrence. Initial therapeutic approach was changed in 139 cases (63.5%). In the subgroup of 81 11C-choline PET/CT scans performed with PSA<1ng/ml, 23 (28.4%) showed a positive result. Initial therapeutic approach was changed in 9 (11.1%). Three (4.8%) out of 63 patients died as per PCa. Conclusions 11C-choline PET/CT demonstrated its effectiveness in PCa surveillance and restaging, even in patients with serum PSA<1ng/ml. The diagnostic performance was different depending on the initial treatment, been higher in patients with non-surgical treatment (AU)

Tratamiento multicomponente del tabaquismo en Atención Primaria: seguimiento transcurridos más de 5 años / Multicomponent treatment of tobacco in primary care: Follow-up over 5years

Objetivos: Analizar la eficacia de un tratamiento multicomponente para dejar de fumar llevado a cabo en Atención Primaria y evaluar la evolución del consumo de tabaco que tuvieron las personas que participaron, transcurridos más de 5 años desde la finalización del tratamiento. Diseño: Estudio longitudinal de 307 personas participantes en un programa multicomponente en formato grupal de deshabituación de tabaco. Emplazamiento: Centro de Salud de Atención Primaria de Santander. Participantes: Personas fumadoras de la Zona Básica de Salud que deseaban dejar de fumar entre 2006 y 2012 y solicitaron ayuda. Intervenciones: Tratamiento multicomponente de 5sesiones presenciales y seguimiento hasta los 12 meses.Mediciones principales: La actividad se evaluó en 263 sujetos, una vez transcurridos más de 5años desde que finalizaron el tratamiento. Los resultados de abstinencia continua y puntual se obtuvieron por autodeclaración y los datos registrados en la historia clínica. La puntual se validó también con cooximetría. Resultados: Al año declararon abstinencia continua el 42,7% de las participantes. Transcurridos entre 5 y 12 años, la abstinencia continua declarada mayor de 12meses fue del 40,7%. No volvieron a fumar desde que finalizaron el tratamiento 66 personas. El 68,0% de las que recayeron realizaron nuevos intentos y de ellas el 45,5% solicitaron ayuda para dejar de fumar. Conclusiones: El tratamiento multicomponente propuesto es eficaz. La abstinencia a los 12 meses predice el mantenimiento a largo plazo y participar en grupos de deshabituación favorece la realización de nuevos intentos en caso de recaída y la solicitud de ayuda para dejar de fumar.(AU)

Objectives: To analyze the effectiveness of a multicomponent treatment for smoking cessation carried out in primary care and to evaluate the evolution of the consumption of tobacco that the people who participated had, more than 5 years after the end of the treatment. Design: Longitudinal study of 307 participants in a multicomponent program in group format of tobacco cessation. Emplacement: Santander (Spain) Primary Care Health Center. Participants: Smokers from the basic health zone who wanted to quit smoking between 2006 and 2012 and requested help. Interventions: Multicomponent treatment of 5face-to-face sessions and follow-up for up to 12 months. Primary measurements: The activity was evaluated in 263 participants more than 5years after the end of treatment. The results of continuous and punctual withdrawal were obtained by self-declaration and the data recorded in the medical record. The punctual was also validated with co-oximetry. Results: After a year 42.7% of participants declared continuous abstinence. From 5 to 12 years later, the continuous declared abstinence further than 12 months was 40.7%. They did not smoke again since the end of the treatment 66 people; 68.0% of those who relapsed made new attempts and 45.5% of them requested help to quit smoking. Conclusions: The proposed multi-component treatment is effective. Abstinence at 12 months predicts long-term maintenance and participating in disabling groups favors further attempts in case of relapse and the request for help to quit smoking.(AU)

[Multicomponent treatment of tobacco in primary care: Follow-up over 5years]. / Tratamiento multicomponente del tabaquismo en Atención Primaria: seguimiento transcurridos más de 5 años.

OBJECTIVES: To analyze the effectiveness of a multicomponent treatment for smoking cessation carried out in primary care and to evaluate the evolution of the consumption of tobacco that the people who participated had, more than 5 years after the end of the treatment. DESIGN: Longitudinal study of 307 participants in a multicomponent program in group format of tobacco cessation. EMPLACEMENT: Santander (Spain) Primary Care Health Center. PARTICIPANTS: Smokers from the basic health zone who wanted to quit smoking between 2006 and 2012 and requested help. INTERVENTIONS: Multicomponent treatment of 5face-to-face sessions and follow-up for up to 12 months. PRIMARY MEASUREMENTS: The activity was evaluated in 263 participants more than 5years after the end of treatment. The results of continuous and punctual withdrawal were obtained by self-declaration and the data recorded in the medical record. The punctual was also validated with co-oximetry. RESULTS: After a year 42.7% of participants declared continuous abstinence. From 5 to 12 years later, the continuous declared abstinence further than 12 months was 40.7%. They did not smoke again since the end of the treatment 66 people; 68.0% of those who relapsed made new attempts and 45.5% of them requested help to quit smoking. CONCLUSIONS: The proposed multi-component treatment is effective. Abstinence at 12 months predicts long-term maintenance and participating in disabling groups favors further attempts in case of relapse and the request for help to quit smoking.

Infiltración del nervio óptico como forma inicial de recaída de la leucemia linfoblástica aguda / Optic nerve infiltration as an initial form of relapse of acute lymphoblastic leukemia

Introducción: La infiltración del nervio óptico como forma inicial de recaída de la leucemia linfoblástica aguda es rara, aunque altamente indicativa de que el sistema nervioso central está involucrado. Objetivo: Actualizar el conocimiento sobre infiltración del nervio óptico como forma inicial de recaída de la leucemia linfoblástica aguda. Métodos: Se realizó una revisión de las publicaciones más relevantes relacionadas con el tema durante los últimos años. La búsqueda y la localización de la información se apoyaron en la elección de palabras clave/descriptores que configuraron el perfil de búsqueda. Se utilizó el MeSH Database de PubMed. Se realizó una extensa revisión en Google Académico y otros megabuscadores de revisión sistemática mediante TripDatabase y Cochrane. Conclusiones: La infiltración directa de células tumorales y las alteraciones hematológicas propias de la enfermedad constituyen los mecanismos fundamentales de la fisiopatogenia. El edema del disco óptico es su signo oftalmoscópico más distintivo. La imagen por resonancia magnética de cráneo, el análisis citológico del fluido cerebroespinal y la biopsia de médula ósea negativas no deben excluir el diagnóstico. La terapia combinada que incluye la radiación localizada constituye una buena opción de tratamiento. Un número considerable de ojos recuperan su agudeza visual y muestran resolución del cuadro infiltrativo(AU)

Introduction: Optic nerve infiltration as an initial form of relapse of acute lymphoblastic leukemia is rare, although it is highly indicative of central nervous system involvement. Objective: To update the knowledge about optic nerve infiltration as an initial form of relapse of acute lymphoblastic leukemia. Methods: A review of the most relevant publications related to the subject during the last years was carried out. The search and localization of information was supported by the choice of keywords/descriptors that configured the search profile. The MeSH Database of PubMed was used. An extensive review was performed in Google Scholar and other systematic review mega search engines using TripDatabase and Cochrane. Conclusions: Direct tumor cell infiltration and disease-specific hematologic alterations are the fundamental mechanisms of pathophysiology. Optic disc edema is the most distinctive ophthalmoscopic sign. Negative cranial magnetic resonance imaging, cytologic analysis of cerebrospinal fluid and bone marrow biopsy should not exclude the diagnosis. Combination therapy including localized radiation is a good treatment option. A considerable number of eyes recover visual acuity and show resolution of the infiltrative picture(AU)

COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case–control study / COVID-19 y sus implicaciones en el curso clínico-radiológico de la esclerosis múltiple: un estudio de casos y controles

Background: Multiple sclerosis (MS) is an immune-mediated disease that has been related to several risk factors such as various viral infections. We carried out this study in order to establish a relationship between COVID-19 infection and MS severity.MethodsIn a case–control study, we recruited patients with relapsing–remitting multiple sclerosis (RRMS). Patients were divided into two groups based on positive COVID-19 PCR at the end of the enrollment phase. Each patient was prospectively followed for 12 months. Demographical, clinical, and past medical history were collected during routine clinical practice. Assessments were performed every six months; MRI was performed at enrollment and 12 months later.ResultsThree hundred and sixty-two patients participated in this study. MS patients with COVID-19 infection had significantly higher increases in the number of MRI lesions (p: 0.019, OR(CI): 6.37(1.54–26.34)) and EDSS scores (p: 0.017), but no difference was found in total annual relapses or relapse rates. COVID-19 infections were positively correlated with EDSS progression (p: 0.02) and the number of new MRI lesions (p: 0.004) and predicted the likelihood of the number of new MRI lesions by an odds of 5.92 (p: 0.018).ConclusionCOVID-19 may lead to higher disability scores in the RRMS population and is associated with developing new Gd-enhancing lesions in MRI imaging. However, no difference was observed between the groups regarding the number of relapses during follow-up. (AU)

Antecedentes: La esclerosis múltiple (EM) es una enfermedad inmunomediada que se ha relacionado con varios factores de riesgo, como diversas infecciones virales. Realizamos este estudio para establecer una relación entre la infección por COVID-19 y la gravedad de la EM.MétodosEn un estudio de casos y controles, reclutamos pacientes con esclerosis múltiple remitente-recurrente (EMRR). Los pacientes se dividieron en dos grupos según la PCR positiva para COVID-19 al final de la fase de inscripción. Cada paciente fue seguido prospectivamente durante 12 meses. Los antecedentes demográficos, clínicos y médicos anteriores se recogieron durante la práctica clínica habitual. Las evaluaciones se realizaron cada 6 meses. La resonancia magnética se realizó en el momento de la inscripción y 12 meses después.ResultadosTrescientos sesenta y dos pacientes participaron en este estudio. Los pacientes con EM con infección por COVID-19 tuvieron aumentos significativamente más altos en el número de lesiones de resonancia magnética (p=0,019; OR=6,37 [IC 95%: 1,54-26,34]) y puntajes EDSS (p=0,017), pero no se encontraron diferencias en el total de recaídas anuales o en las tasas de recaída. Las infecciones por COVID-19 se correlacionaron positivamente con la progresión de EDSS (p=0,02) y la cantidad de nuevas lesiones en la resonancia magnética (p=0,004) y predijeron la probabilidad de la cantidad de nuevas lesiones en la resonancia magnética con una probabilidad de 5,92 (p=0,018).ConclusiónCOVID-19 puede conducir a puntajes de discapacidad más altos en la población de EMRR y está asociado con el desarrollo de nuevas lesiones realzadas con Gd en imágenes de resonancia magnética. Sin embargo, no se observó diferencia entre los grupos en cuanto al número de recaídas durante el seguimiento. (AU)

Recaídas locorregionales tras mastectomías preservadoras y reconstrucción inmediata en mujeres con cáncer de mama / Locoregional relapse after sparing mastectomies and immediate reconstruction in women with breast cancer

Introducción: Durante los últimos años, los cambios culturales de la sociedad actual y la mejora en la valoración del riesgo han incrementado la indicación de las mastectomías en mujeres con cáncer de mama. Diversos estudios han confirmado la seguridad oncológica de la mastectomías preservadoras y reconstrucción inmediata. El objetivo de este estudio es analizar la incidencia de recaídas locorregionales de este procedimiento y su impacto en la reconstrucción y la supervivencia global. Pacientes y métodos: Estudio prospectivo de pacientes con un carcinoma de mama que realizaron una mastectomía preservadora y reconstrucción inmediata. Se analizaron las recaídas locorregionales, el tratamiento de las mismas y la capacidad de preservar la reconstrucción, así como su impacto en la supervivencia. Resultados: El grupo a estudio lo constituyen 271 mujeres con carcinoma mamario tratadas mediante una mastectomía ahorradora de piel y reconstrucción inmediata. El seguimiento medio fue de 7,98 años y durante el mismo se diagnosticaron 18 recaídas locorregionales (6,6%): 72,2% en el colgajo de la mastectomía y 27,8% ganglionares. No se evidenciaron diferencias significativas en las características patológicas del tumor primario entre las pacientes con y sin una recaída locorregional, aunque el porcentaje de mujeres con tumores hormonosensibles fue superior en el grupo sin recaída. Las pacientes con recaída ganglionar presentaban tumores de mayor tamaño (el 80% T2-T3) y el 60% tenían metástasis axilares al diagnóstico vs. 7,7% de las mujeres con recaída en piel (p = 0,047). Todas las pacientes intervenidas de una recaída locorregional preservaron su reconstrucción. La incidencia de metástasis y muertes fue significativamente mayor en las pacientes con una recaída, causando una disminución no significativa de la supervivencia global. (AU)

Introduction: In recent years, cultural changes in today's society and improved risk assessment have increased the indication for mastectomies in women with breast cancer. Various studies have confirmed the oncological safety of sparing mastectomies and immediate reconstruction. The objective of this study is to analyze the incidence of locoregional relapses of this procedure and its impact on reconstruction and overall survival. Patients and methods: Prospective study of patients with breast carcinoma who underwent a sparing mastectomy and immediate reconstruction. Locoregional relapses and their treatment and their impact on survival were analyzed. Results: The study group is made up of 271 women with breast carcinoma treated with a skin-sparing mastectomy and immediate reconstruction. The mean follow-up was 7.98 years and during the same 18 locoregional relapses (6.6%) were diagnosed: 72.2% in the mastectomy flap and 27.8% lymph node. There were no significant differences in the pathological characteristics of the primary tumor between patients with and without locoregional relapse, although the percentage of women with hormone-sensitive tumors was higher in the group without relapse. Patients with lymph node relapse had larger tumors (80% T2–T3) and 60% had axillary metastases at diagnosis, compared to 7.7% of women with skin relapse (p = 0.047). All patients operated on for locoregional relapse preserved their reconstruction. The incidence of metastases and deaths was significantly higher in patients with a relapse, causing a non-significant decrease in overall survival. (AU)

COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.

BACKGROUND: Multiple sclerosis (MS) is an immune-mediated disease that has been related to several risk factors such as various viral infections. We carried out this study in order to establish a relationship between COVID-19 infection and MS severity. METHODS: In a case-control study, we recruited patients with relapsing-remitting multiple sclerosis (RRMS). Patients were divided into two groups based on positive COVID-19 PCR at the end of the enrollment phase. Each patient was prospectively followed for 12 months. Demographical, clinical, and past medical history were collected during routine clinical practice. Assessments were performed every six months; MRI was performed at enrollment and 12 months later. RESULTS: Three hundred and sixty-two patients participated in this study. MS patients with COVID-19 infection had significantly higher increases in the number of MRI lesions (p: 0.019, OR(CI): 6.37(1.54-26.34)) and EDSS scores (p: 0.017), but no difference was found in total annual relapses or relapse rates. COVID-19 infections were positively correlated with EDSS progression (p: 0.02) and the number of new MRI lesions (p: 0.004) and predicted the likelihood of the number of new MRI lesions by an odds of 5.92 (p: 0.018). CONCLUSION: COVID-19 may lead to higher disability scores in the RRMS population and is associated with developing new Gd-enhancing lesions in MRI imaging. However, no difference was observed between the groups regarding the number of relapses during follow-up.

Effectiveness of 11C-choline PET/CT in prostate cancer surveillance.

AIM: Our aim was to analyse the performance of [11C]choline PET/CT in prostate cancer (PCa) surveillance, especially in patients with prostate specific antigen (PSA) < 1 ng/mL. MATERIAL AND METHODS: Three hundred and twenty-nine [11C]choline PET/CT examinations from 191 patients (68.2 ±â€¯7.2 years) submitted for PCa surveillance or biochemical recurrence were retrospectively evaluated. PSA at study was 13.0 ±â€¯84.2 ng/mL. Main initial treatment was radical prostatectomy (RP) in 81 patients, and other treatments (radiotherapy, chemotherapy, hormonotherapy) in 110. PET/CT was acquired 20' after injection of 555-740 MBq of [11C]choline. Minimum follow-up was 12 months. RESULTS: Two hundred and nineteen (66.6%) out of the 329 PET/CT examinations were positive. The percentage of positive examinations was significantly higher in patients with other initial treatment than RP compared to patients with RP (85.6% vs. 43.6%, respectively). One hundred and thirty PET/CT (59.4%) showed local recurrence, 48 (21.9%) distant recurrence, and 41 (18.7%) local plus distant recurrence. Initial therapeutic approach was changed in 139 cases (63.5%). In the subgroup of 81 [11C]choline PET/CT scans performed with PSA < 1 ng/mL, 23 (28.4%) showed a positive result. Initial therapeutic approach was changed in 9 (11.1%). Three (4.8%) out of 63 patients died as per PCa. CONCLUSION: [11C]choline PET/CT demonstrated its effectiveness in PCa surveillance and restaging, even in patients with serum PSA < 1 ng/mL. The diagnostic performance was different depending on the initial treatment, been higher in patients with non-surgical treatment.

Locoregional relapse after sparing mastectomies and immediate reconstruction in women with breast cancer.

INTRODUCTION: In recent years, cultural changes in today's society and improved risk assessment have increased the indication for mastectomies in women with breast cancer. Various studies have confirmed the oncological safety of sparing mastectomies and immediate reconstruction. The objective of this study is to analyze the incidence of locoregional relapses of this procedure and its impact on reconstruction and overall survival. PATIENTS AND METHODS: Prospective study of patients with breast carcinoma who underwent a sparing mastectomy and immediate reconstruction. Locoregional relapses and their treatment and their impact on survival were analyzed. RESULTS: The study group is made up of 271 women with breast carcinoma treated with a skin-sparing mastectomy and immediate reconstruction. The mean follow-up was 7.98 years and during the same 18 locoregional relapses (6.6%) were diagnosed: 72.2% in the mastectomy flap and 27.8% lymph node. There were no significant differences in the pathological characteristics of the primary tumor between patients with and without locoregional relapse, although the percentage of women with hormone-sensitive tumors was higher in the group without relapse. Patients with lymph node relapse had larger tumors (80% T2-T3) and 60% had axillary metastases at diagnosis, compared to 7.7% of women with skin relapse (p = 0.047). All patients operated on for locoregional relapse preserved their reconstruction. The incidence of metastases and deaths was significantly higher in patients with a relapse, causing a non-significant decrease in overall survival. CONCLUSION: Locoregional relapses are a rare event in women with a sparing mastectomy and immediate reconstruction. Most patients with locoregional relapse can preserve their initial reconstruction through local resection of the tumor and adjuvant and / or neoadjuvant therapies.

Recaída en el consumo de alcohol después del trasplante de hígado por hepatopatía alcohólica / Alcohol relapse after liver transplantation for alcoholic liver disease

Introducción. La enfermedad hepática inducida por uso de alcohol se ha considerado una enferme-dad autoinfligida que limitaba el acceso al trasplante. Actualmente es una de las principales indicacio-nes de trasplante hepático en Colombia y el mundo, con excelente sobrevida. Metodología. Estudio descriptivo observacional donde se realizó una caracterización de los pacientes con trasplante hepá-tico por hepatopatía alcohólica en una institución de cuarto nivel, que incluyó un estudio cualitativo de la recaída en el consumo de alcohol postrasplante. Resultados. De 87 pacientes de una cohorte inicial de 96 pacientes trasplantados entre 2003 y 2021, se describieron características sociodemo-gráficas, comorbilidades previas y adquiridas posterior al trasplante, supervivencia del paciente y del injerto, y factores de riesgo asociados al consumo de alcohol. Adicionalmente, a 65 pacientes se les pudo realizar una entrevista estructurada para evaluar la recaída en el consumo de alcohol, 41,53 % volvieron a consumir alcohol; 23,07 % en patrón de riesgo de recaída y 18,46 % en patrón de slip (desliz). El antecedente de hepatitis alcohólica tuvo un RR de 3,273 (1,464­7,314) y p=0,007 para recaída en el consumo de alcohol, y la comorbilidad psiquiátrica un RR de 2,395 (1,002­5,722) y p=0,047. Finalmente, haber presentado al menos una recaída postrasplante tuvo un RR de 5,556 (1,499­20,588) con p=0,005 para rechazo del injerto. Conclusiones. La recaída en el consumo de alcohol fue frecuente, la hepatitis alcohólica previa y la comorbilidad psiquiátrica son factores de riesgo asociados. La recaída se asoció a rechazo del injerto sin afectar la sobrevida del paciente.

Introduction. Alcohol-induced liver disease has been considered a self-inflicted disease that limited access to transplantation. It is currently one of the main indications for liver transplantation in Colom-bia and the world, with excellent survival. Methodology. Observational descriptive study where a characterization of liver transplant patients due to alcoholic liver disease was carried out in a fourth level institution, which included a qualitative study of relapse in post-transplant alcohol consumption. Results. Of 87 patients from an initial cohort of 96 transplant patients between 2003 and 2021, sociodemographic characteristics, previous and acquired post-transplant comorbidities, patient and graft survival, and risk factors associated with alcohol consumption were described. Additionally, 65 patients were able to undergo a structured interview to assess relapse in alcohol consumption, 41.53% returned to alcohol consumption; 23.07% in risk relapse pattern, and 18.46% in slip pattern. The history of alcoholic hepatitis had a RR of 3.273 (1.464-7.314) and a p=0.007 for relapse in alcohol consumption, and psychiatric comorbidity a RR of 2.395 (1.002-5.722) and a p=0.047. Finally, having presented at least one post-transplant relapse had a RR of 5.556 (1.499-20.588) with ap=0.005 for graft rejection. Conclusions. Relapse in alcohol consumption was fre-quent, previous alcoholic hepatitis and psychiatric comorbidity were associated risk factors. Relapse was associated with graft rejection without affecting patient survival.

Inteligencia emocional como mediador del craving y el riesgo de recaída en adultos en tratamiento por consumo de alcohol

Objetivos: Analizar el efecto de craving sobre el riesgo de recaída en adultos en tratamiento por alcohol, considerando la Inteligencia Emocional Percibida (IEP) como mediador. Materiales y métodos: Estudio descriptivo, transversal, predictivo, de comprobación de modelo con análisis de mediación. La muestra fue de 274 adultos internos en Centros de Rehabilitación contra las Adicciones (CRCA). Los instrumentos utilizados fueron una Cédula de Datos Sociodemográficos, Cuestionario de Craving por Alcohol, Inventario de Cociente Emocional y Cuestionario de Variables Predictoras de Abandono y Adhesión al Tratamiento. Resultados: Existe una relación inversa entre la IEP, el riesgo de recaída (r = -,381, p <,001) y el craving (r = -,354, p <,001). El craving y el riesgo de recaída se relacionaron positivamente (r = ,218, p <,001). Se reporta un efecto total significativo del craving sobre el riesgo de recaída cuando es mediado por la IE, el cual explica el 11 % de la varianza (B = ,1389; t = 5,688; p <,001). Conclusiones: Los resultados de este estudio indican que IEP se asocia inversamente con el craving y el riesgo de recaída, además de que la IEP desempeña un papel significativo como mediador en esta relación. Esto sugiere que las personas con altos niveles de IEP disponen de más recursos para gestionar sus emociones, lo que podría ayudar a reducir las conductas de craving y, consecuentemente, sufrir un menor riesgo de recaída en el consumo de alcohol.

Objectives: To analyze the effect of craving on the risk of relapse in adults undergoing alcohol treatment, considering the Perceived Emotional Intelligence (PEI) as a mediator. Materials and methods: Descriptive, cross-sectional, predictive study, model checking with mediation analysis. The sample consisted of 274 adults interned in Rehabilitation Centers against Addictions (CRCA). The instruments used were a Sociodemographic Data Card, Alcohol Craving Questionnaire, Emotional Quotient Inventory and Questionnaire of Variables Predictors of Abandonment and Adherence to Treatment. Results: There is an inverse relationship between PEI, the risk of relapse (r = -, 381, p <,001) and craving (r = -, 354, p <,001). Craving and risk of relapse were positively related (r = ,218, p <,001). A significant total effect of craving on the risk of relapse is reported when mediated by EI, which explains 11% of the variance (B = ,1389; t = 5,688; p <,001). Conclusions: The results of this study indicate that PEI is inversely associated with craving and risk of relapse, and that PEI plays a significant role as a mediator in this relationship. This suggests the notion that people with high PEI levels have more resources to manage their emotions, which could help reduce craving behaviors and consequently, suffer a lower risk of relapse into alcohol consumption.

Unilateral perineal hernia surgery. Case report / Cirugía unilateral de hernia perineal. Reporte de caso

ABSTRACT Perineal hernia results from weakening and/or the inability of the pelvic diaphragm to support the rectal wall, promoting caudal displacement of abdominal or pelvic organs in the perineum. Unneutered male dogs aged between 7 and 10 years are the most affected, being rare in females. The main clinical signs are unilateral or bilateral swelling of the perineal region, associated or not with tenesmus, dysuria, urinary and/or fecal incontinence, anuria and pain during defecation. The diagnosis is based on clinical history, anamnesis, physical examination, and complementary tests such as radiography and ultrasound. Clinical treatment can be done in some cases, but surgical intervention is required to resolve the problem. The present work aims to report the case of a patient treated at the FullPet Veterinary Clinic in Guarulhos, São Paulo, Brazil, a 7-year-old male Yorkshire canine, unneutered, weighing 4.5 kg. The same was submitted to surgery by the traditional method of suture with nylon thread and enteropexy. When there was recurrence, surgical reintervention was necessary to correct the hernia using a polypropylene mesh.

RESUMEN La hernia perineal resulta del debilitamiento y/o incapacidad del diafragma pélvico para sostener la pared rectal, lo que promueve el desplazamiento caudal de los órganos abdominales o pélvicos en el perineo. Los perros machos no castrados de entre 7 y 10 años son los más afectados, siendo raro en las hembras. Los principales signos clínicos son tumefacción unilateral o bilateral de la región perineal, asociada o no a tenesmo, disuria, incontinencia urinaria y/o fecal, anuria y dolor durante la defecación. El diagnóstico se basa en la historia clínica, la anamnesis, el examen físico y pruebas complementarias como la radiografía simple y la ecografía. El tratamiento clínico se puede hacer en algunos casos, pero se requiere una intervención quirúrgica para resolver el problema. El presente trabajo tiene como objetivo relatar el caso de un paciente atendido en la Clínica Veterinaria FullPet de Guarulhos, São Paulo, Brasil, un canino Yorkshire macho de 7 años, sin castrar, con un peso de 4,5 kg. Fue intervenido quirúrgicamente por el método tradicional de sutura con hilo de nylon y enteropexia. Cuando hubo recidiva, fue necesaria la reintervención quirúrgica para corregir la hernia mediante una malla de polipropileno.

Patología dual en pacientes inmigrantes con Trastorno por Uso de Alcohol: seguimiento tras dos años de tratamiento / Dual pathology in immigrant patients with Alcohol Use Disorder: follow-up after two years of treatment

Introducción: Existe una elevada prevalencia de trastornos psiquiátricos en el trastorno por uso de alcohol. Lapresencia de patología dual en el paciente disminuye el mantenimiento de la abstinencia y aumenta la probabilidad derecaída, lo que complica el tratamiento. Los objetivos de esteestudio son: Analizar la evolución a dos años de tratamiento de una población de pacientes inmigrantes con trastorno por uso de alcohol asociado a trastornos psiquiátricos,comparándola con una muestra de pacientes inmigrantes sinpatología dual e investigar los diagnósticos de patología psiquiátrica asociada al trastorno por uso de alcohol.Metodología. Se compararon dos poblaciones de pacientes inmigrantes con trastorno por uso de alcohol (DSM-5),una con trastornos psiquiátricos asociados, compuesta por219 pacientes y otra de 169 pacientes sin patología dual.Resultados y conclusiones. Los trastornos psiquiátricosmás frecuentes asociados al trastorno por uso de alcoholson el de personalidad (51,6%), el adaptativo y depresivo(22,8%), los de ansiedad (15,5%), los de conducta alimentaria y obsesivos compulsivos (5,9%), el bipolar (5%) y el deesquizofrenia (2,3%). El seguimiento a 2 años de tratamientopresenta que el 27% de la población inmigrante con patología dual se mantiene en abstinencia frente al 41,4% de la quesolo padece trastorno por uso de alcohol: Se constata unapeor evolución en los pacientes con patología dual. (AU)

Introduction: There is a high prevalence of comorbidpsychiatric disorders in alcohol abuse disorder. The presenceof dual diagnosis in patients decreases the maintenance ofabstinence and increases the likelihood of relapse, whichmakes treatment more complicated. The aims of thisstudy are: to investigate the progression along two yearsof treatment of a sample of migrant patients affected byalcohol abuse disorder associated with psychiatric disorders,comparing it with a sample of migrant patients withoutdual diagnosis and investigating the diagnoses of comorbidpsychiatric pathology with alcohol abuse disorder.Methods. Two populations of migrant patients withalcohol abuse disorder (DSM-5) were compared, one withcomorbid psychiatric disorders consisting of 219 patientsand the other of 169 patients without dual diagnosis.Results and conclusions. The most frequent psychiatricdisorders associated with alcohol use disorder are personalitydisorders (51,6%), adjustment and depressive disorders(22,8%), anxiety disorders (15,5%), eating disorders andobsessive-compulsive disorders (5,9%), bipolar disorders(5%) and schizophrenia (2,3%). The two-year follow-uptreatment shows that 27% of immigrant sample with dualdiagnosis remains in abstinence compared to 41,4% of thosewho only suffer from alcohol use disorder: Worse outcomesare observed in patients with dual diagnosis. (AU)